Results 41 to 50 of about 20,750 (203)
Rapid Response to Trametinib Combined With Chemotherapy for Infant BRAF‐Fused Chiasmatic Glioma
Pediatric Blood &Cancer, EarlyView.ABSTRACT Infants, less than 1 year, with chiasmatic gliomas (ICG) present a major therapeutic challenge due to large tumor size, decreased vision, rapid progression, and poor response to vincristine/carboplatin chemotherapy. The majority have a BRAF fusion, which may respond to downstream MEK inhibitors but response time is slow. There are no safety or
Helen Toledano +7 more
wiley +1 more source
Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma
Antioxidants, 2023 The use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients has significantly improved progression-free and overall survival of metastatic melanoma patients.
Marie Angèle Cucci +7 more
doaj +1 more source
Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect [PDF]
, 2017 Intraocular metastasis of cutaneous melanoma is extremely infrequent. This typically occurs in advanced metastatic disease and has a poor survival prognosis. The most frequent reported treatment is radiotherapy.
Fernández, Ricardo +5 more
core +3 more sources
Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells
Molecular Oncology, EarlyView.We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller +17 more
wiley +1 more source
New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy [PDF]
, 2014 Development of selective inhibitors of BRAF has improved the survival of patients with BRAF-mutant melanoma. The progression-free survival after treatment with a BRAF inhibitor is modest, however, and BRAF inhibitors induce cutaneous toxicity, likely due
Luke, Jason J, Ott, Patrick A
core +1 more source
Advanced Science, EarlyView.This study reports that SBNO1 protein is upregulated in several cancer entities. SBNO1 protein interacts with the basal transcription factor TFIID via TAF4, enabling its recruitment to transcription start sites and the modulation of target gene expression.
Sarah Fritzsche +21 more
wiley +1 more source
Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients [PDF]
, 2015 This study shows radiosensitization by BRAF inhibitors in clinical practice and ex vivo by fluorescence in situ hybridization of chromosomal breaks.
Bauch, J. +23 more
core +2 more sources
Advanced Science, EarlyView.This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey +6 more
wiley +1 more source
Unusual Skin Carcinomas Induced by BRAF Inhibitor for Metastatic Melanoma: A Case Report [PDF]
Journal of Clinical and Diagnostic Research, 2017 The most frequently reported skin tumours during treatment with targeted therapies for BRAF (B type Rapidly Accelerated Fibrosarcoma kinase) mutated metastatic melanoma are squamous cell carcinomas (SCCs).
Stefano Cavalieri +4 more
doaj +1 more source
Frontiers in Oncology, 2023 BackgroundDifferentiated thyroid cancer accounts for the majority of thyroid cancers and has a good prognosis after standard treatment. However, there are still some complex and refractory thyroid cancers, including locally advanced differentiated ...
Xue Peng +3 more
doaj +1 more source